PRIVILEGED & CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT DO NOT DISTRIBUTE WITHOUT PRIOR AUTHORIZATION FROM CALDERWOOD & HARKNESS LLP
CALDERWOOD & HARKNESS LLP 1700 Market Street, 42nd Floor Philadelphia, Pennsylvania 19103
MEMORANDUM
August 18, 2024
TO: Thomas F. Holbrook, General Counsel & Secretary, Penterra Pharmaceuticals Corp. Natalie Reiner, SVP, Corporate Development, Penterra Pharmaceuticals Corp.
FROM: Megan Chu, Associate, Calderwood & Harkness LLP Derek Okonkwo, Associate, Calderwood & Harkness LLP
REVIEWED BY: Oliver Mackenzie, Partner, Calderwood & Harkness LLP
RE: Analysis of Veridian Biosciences, Inc.'s Compliance with Notification Obligations Under Section 5.1(b) of the Stock Purchase Agreement dated June 10, 2024
MATTER NO.: 1018-00008
This memorandum is a privileged and confidential attorney-client communication and constitutes attorney work product prepared in anticipation of litigation. It is intended solely for the use of the addressees identified above. This memorandum contains our preliminary legal analysis and should not be disclosed to, or relied upon by, any third party without the prior written authorization of Calderwood & Harkness LLP. Any unauthorized disclosure may result in a waiver of applicable privileges.
I. Executive Summary
This memorandum evaluates whether Veridian Biosciences, Inc. ("Veridian" or the "Company") complied with its notification obligations under Section 5.1(b) of the Stock Purchase Agreement dated June 10, 2024 (the "SPA") between Penterra Pharmaceuticals Corp. ("Penterra" or "PPC") and the stockholders of Veridian with respect to the data generated by the Marlowe Asset Management-2 Phase II clinical trial Data Monitoring Committee ("DMC") interim analysis conducted on August 14, 2024. The purpose of this memorandum is to provide Penterra's in-house legal and corporate development teams with a detailed assessment of both the timeliness and the completeness of Veridian's notification, and to identify the implications of any deficiencies for Penterra's rights under the SPA, including its termination rights and the satisfaction of closing conditions.
Our principal conclusions are as follows:
Veridian provided notification to Penterra on August 16, 2024 — approximately two calendar days after the DMC conducted its interim analysis on August 14, 2024. While a two-day gap is not, standing alone, a grossly delayed response, the notification raises material concerns on two fronts. First, with respect to timeliness, we believe that the severity of the DMC findings — including a 23.4% incidence of Grade ≥3 cytokine release syndrome ("CRS") in the treatment arm, seven treatment-related deaths, and a non-statistically significant overall response rate — warranted more immediate notice, particularly given the specific inclusion of DMC recommendations in Section 5.1(b)(vi) and the magnitude of the transaction. Second, and more significantly, the notification was materially incomplete: it omitted the treatment-related death count entirely, failed to provide specific quantitative CRS incidence rates, did not disclose the overall response rate data with accompanying statistical significance, and did not attach or reference the underlying DMC report, meeting minutes, or statistical tables.
These deficiencies bear on Penterra's ability to assess whether the Marlowe Asset Management-2 interim analysis results constitute a "Material Adverse Effect" under SPA § 1.1, whether Veridian's representations and warranties remain true and correct as required by closing condition § 7.2(a), and whether a Material Adverse Effect has occurred since the date of the SPA as contemplated by closing condition § 7.2(b). Under the express terms of the SPA, delivery of a notification under Section 5.1(b) does not cure any breach of representation or warranty, does not limit Penterra's rights, and does not affect the closing conditions. The notification deficiencies identified herein therefore do not alter Penterra's substantive rights but do strengthen the evidentiary record supporting Penterra's position regarding Veridian's performance of its covenants.
We recommend that Penterra take the following immediate steps: (a) send a formal written request through Calderwood & Harkness to Veridian's counsel at Zalcourt Archer & Cole LLP demanding the full DMC interim analysis report, meeting minutes, adverse event data, and all related regulatory correspondence; (b) carefully document and preserve the timeline and content of all communications received from Veridian for use in any future termination proceeding or litigation; and (c) coordinate with Broadleaf Scientific Consulting LLC to independently assess the DMC data as it becomes available. We further recommend ongoing real-time monitoring of Veridian's compliance with all Section 5.1(b) obligations, including with respect to the anticipated FDA regulatory response to the Marlowe Asset Management-2 safety signal, which we understand may be forthcoming.
II. Background
A. The Transaction
Penterra Pharmaceuticals Corp. ("Penterra" or "PPC"), a Delaware corporation publicly traded on the Nasdaq Global Select Market under the ticker symbol "PPCA," entered into the Stock Purchase Agreement dated June 10, 2024 (the "SPA") to acquire one hundred percent (100%) of the outstanding capital stock of Veridian Biosciences, Inc. ("Veridian" or the "Company") for aggregate consideration of Nine Hundred Million Dollars ($900,000,000) in cash, subject to customary adjustments for working capital, indebtedness, and transaction expenses as set forth in Article II of the SPA.
Veridian is a privately held, clinical-stage biotechnology company organized under the laws of the State of Delaware, with its principal offices located at 550 Gateway Drive, Cambridge, Massachusetts 02142. The Company is focused on the development of immuno-oncology therapeutics leveraging its proprietary VeriTCE (T-cell engager) platform, a technology designed to redirect endogenous T cells to recognize and destroy tumor cells expressing specific surface antigens. Veridian's clinical-stage pipeline consists of three compounds, the most advanced of which is VRD-4187, a bispecific T-cell engager targeting DLL3-expressing tumors, principally in small cell lung cancer ("SCLC"). At the time of execution of the SPA, VRD-4187 was in Phase II clinical trials and constituted the principal asset underpinning the acquisition valuation.
The SPA was executed by Dr. Anand Rajagopal, Chief Executive Officer, on behalf of Penterra, and by Dr. Julian Marek, Chief Executive Officer, on behalf of Veridian, with David Ng, Managing Partner of Crestline Ventures, LP (Veridian's lead institutional investor), serving as the Stockholder Representative for purposes of the post-closing indemnification and other provisions of the SPA. The transaction is structured as a stock purchase, with the Sellers being the holders of all outstanding capital stock, options, and warrants of Veridian, and with Veridian becoming a wholly owned subsidiary of Penterra upon the Closing.
The SPA is governed by and construed in accordance with the laws of the State of Delaware, without regard to conflict-of-laws principles. Section 10.6 of the SPA provides for the exclusive jurisdiction of the Court of Chancery of the State of Delaware (or, if the Court of Chancery declines jurisdiction, the United States District Court for the District of Delaware) over any dispute arising out of or relating to the SPA. The Sellers are represented in the transaction by Zalcourt Archer & Cole LLP, with Rebecca Whitmore, Partner, serving as lead counsel, and Jonathan Pratt, Associate, serving as a primary contact for day-to-day transaction matters. Penterra is represented by our firm, Calderwood & Harkness LLP.
B. VRD-4187 and the Marlowe Asset Management-2 Trial
VRD-4187 is Veridian's lead clinical candidate and the centerpiece of the Company's pipeline. VRD-4187 is being developed under Investigational New Drug Application ("IND") No. 154832, submitted to the United States Food and Drug Administration ("FDA"). The compound is a bispecific T-cell engager designed to simultaneously bind the DLL3 antigen on the surface of tumor cells and the CD3 receptor on T cells, thereby bringing cytotoxic T cells into close proximity with tumor cells and facilitating tumor cell lysis. DLL3 is a Notch pathway ligand that is highly expressed on the surface of SCLC cells and other neuroendocrine tumors, making it an attractive therapeutic target in indications where treatment options are limited and prognosis is poor.
The Marlowe Asset Management-2 trial (ClinicalTrials.gov Identifier: NCT05837291) is a randomized, open-label Phase II clinical trial evaluating the safety and efficacy of VRD-4187 as a second-line therapy in patients with extensive-stage SCLC who have progressed following platinum-based chemotherapy. The trial was designed with a treatment arm receiving VRD-4187 in combination with standard-of-care topotecan and a control arm receiving topotecan alone. The trial enrolled a total of 387 patients across 42 clinical sites in the United States and the European Union, with 194 patients randomized to the VRD-4187 treatment arm and 193 patients randomized to the control arm. The primary endpoints of the trial are overall response rate ("ORR") and progression-free survival ("PFS"), with overall survival ("OS") as a key secondary endpoint and safety as a co-primary endpoint.
As is standard for a Phase II trial of this nature, an independent Data Monitoring Committee ("DMC") was established to conduct periodic safety reviews and pre-specified interim analyses. The DMC is composed of independent oncologists and biostatisticians who are unblinded to the treatment assignments and who have access to the accumulating safety and efficacy data. The DMC's charter authorizes it to recommend, among other things, continuation of the trial without modification, protocol amendments (including dose modifications), suspension of enrollment, or early termination of the trial.
On August 14, 2024, the DMC conducted a pre-specified interim analysis of the Marlowe Asset Management-2 trial. The DMC's findings, as subsequently disclosed to Penterra (and as supplemented through Penterra's follow-up inquiries), were as follows:
•  Grade ≥3 Cytokine Release Syndrome (CRS) Incidence: 23.4% in the VRD-4187 treatment arm compared to 4.1% in the control arm, representing a differential of 19.3 percentage points. CRS is a systemic inflammatory response triggered by the activation of T cells and is a known class effect of T-cell engager therapies, though an incidence rate of 23.4% at Grade ≥3 severity is significantly elevated relative to the rates observed in the Phase I dose-escalation study of VRD-4187 and relative to the safety profiles of comparable T-cell engager programs.
•  Treatment-Related Deaths: Seven (7) deaths in the VRD-4187 treatment arm (3.6% of 194 patients) compared to one (1) death in the control arm (0.5% of 193 patients). The treatment-related death rate in the VRD-4187 arm is notably elevated and represents a serious safety signal that would be expected to attract immediate regulatory scrutiny.
•  Overall Response Rate (ORR): 31.4% in the VRD-4187 treatment arm compared to 28.9% in the control arm, with a p-value of 0.58, indicating that the difference was not statistically significant. The absence of a statistically significant efficacy signal at the interim analysis, combined with the elevated safety profile, raises fundamental questions about the risk-benefit profile of VRD-4187 in this indication and patient population.
•  DMC Recommendation: The DMC recommended suspension of new patient enrollment in the Marlowe Asset Management-2 trial and implementation of dose modifications for patients currently receiving VRD-4187, pending further review of the safety data.
These findings form the factual predicate for the notification analysis that is the subject of this memorandum. A separate and comprehensive analysis of whether the Marlowe Asset Management-2 interim analysis results constitute a "Material Adverse Effect" under SPA § 1.1 is currently being prepared by our team and is expected to be delivered to Penterra by August 25, 2024.
C. Chronology of Events and Notification
The following chronology sets forth the key events relevant to our analysis of Veridian's compliance with Section 5.1(b):
August 14, 2024 (Wednesday): The Marlowe Asset Management-2 DMC convenes and conducts the pre-specified interim analysis. The DMC's findings, as described above, are communicated to the trial sponsor (Veridian) through the DMC's established communication channels. Based on standard DMC procedures and the organizational structure disclosed in the DMC charter (a copy of which was made available to Penterra during due diligence), the DMC's recommendations are transmitted directly to the trial sponsor's designated unblinded representatives. At Veridian, the senior management personnel present at or notified of the DMC meeting results on this date include Dr. Julian Marek (CEO), Dr. Priya Chandrasekaran (Chief Scientific Officer), and Dr. Anne-Marie Fontaine (Vice President, Regulatory Affairs). We understand, based on Veridian's prior disclosures regarding its clinical trial governance procedures, that DMC communications are transmitted to the VP, Regulatory Affairs in the first instance, who then escalates to the CEO and CSO.
August 15, 2024 (Thursday): No notification is received by Penterra from Veridian or from Veridian's counsel. We have no direct visibility into Veridian's internal activities on this date, but it is reasonable to infer that the Company was reviewing the DMC findings internally and consulting with its outside legal counsel at Zalcourt Archer & Cole LLP.
August 16, 2024 (Friday): Penterra receives notification from Veridian regarding the DMC findings, purportedly pursuant to Section 5.1(b) of the SPA. The notification is delivered via email from Rachel Stein-Goldberg (General Counsel, Veridian) to Thomas F. Holbrook (General Counsel, Penterra), with a copy to Natalie Reiner (SVP, Corporate Development, Penterra). A separate, contemporaneous communication is transmitted from Rebecca Whitmore (Zalcourt Archer & Cole LLP) to Oliver Mackenzie (Calderwood & Harkness LLP). The content and deficiencies of this notification are analyzed in detail in Section V below.
August 19, 2024 (Monday): Broadleaf Scientific Consulting LLC, an independent clinical and regulatory consulting firm retained by Penterra in connection with the transaction, delivers a supplemental clinical assessment to Penterra reviewing the DMC data. The assessment, prepared under the supervision of Dr. Raymond Kapoor (Managing Director), is based on information obtained through Penterra's follow-up requests to Veridian and through Broadleaf's independent analysis of publicly available clinical data and literature regarding VRD-4187 and comparable T-cell engager therapies.
August 22, 2024 (Thursday): The FDA imposes a partial clinical hold on VRD-4187 under IND 154832, directing Veridian to suspend dosing of new patients pending submission and FDA review of a safety report and protocol amendment. This subsequent event is not yet the subject of the notification analysis in this memorandum, though we note that Veridian's obligation to notify Penterra regarding the FDA partial clinical hold will also arise under Section 5.1(b)(iv) (governmental authority notices) and Section 5.1(b)(vi) (material clinical trial developments), and should be separately monitored and analyzed.
III. Relevant SPA Provisions
A. Section 5.1(b) — Notification Covenants
Section 5.1(b) of the SPA establishes the affirmative notification obligations of Veridian and the Sellers during the interim period between signing and the earlier of the Closing or the termination of the SPA. The operative text of Section 5.1(b) provides as follows:
"From the date of this Agreement until the earlier of the Closing or the termination of this Agreement in accordance with Article VIII, the Company shall promptly notify Buyer in writing of:
(i) any event, circumstance, development, or occurrence arising after the date of this Agreement that has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
(ii) any event, circumstance, or development arising after the date of this Agreement that would reasonably be expected to cause any representation or warranty of the Sellers set forth in Article III to be untrue or inaccurate in any material respect as of the Closing Date;
(iii) any material breach of any covenant or obligation of the Company or the Sellers under this Agreement;
(iv) any notice or communication from any Governmental Authority relating to the Transactions or the business of the Company;
(v) any litigation, investigation, or proceeding commenced or, to the Company's Knowledge, threatened against the Company that, if existing as of the date hereof, would be required to be disclosed pursuant to Section 3.10; and
(vi) any material development relating to any pending clinical trial of the Company, including any data monitoring committee recommendation, adverse event report, or regulatory communication."
Section 5.1(b) further provides:
"The delivery of any notification pursuant to this Section 5.1(b) shall not (A) be deemed to cure any breach of any representation, warranty, covenant, or obligation under this Agreement, (B) limit or otherwise affect the rights or remedies available to Buyer under this Agreement, including Buyer's right to terminate this Agreement pursuant to Article VIII, or (C) be deemed to satisfy any of the conditions set forth in Section 7.2."
This savings clause is of critical importance. It means that even if Veridian's notification were deemed timely and complete, the underlying facts giving rise to the notification obligation — namely, the Marlowe Asset Management-2 DMC findings — may independently give rise to a failure of closing conditions under Sections 7.2(a) and 7.2(b) or a termination right under Section 8.1(d). Conversely, any deficiency in the notification itself constitutes a separate and independent basis for covenant noncompliance, distinct from the substantive question of whether a Material Adverse Effect has occurred.
B. Definition of "Promptly"
The SPA does not define the term "promptly." Section 1.1 of the SPA, which contains the defined terms used throughout the Agreement, includes definitions for "Business Day," "Knowledge," "Material Adverse Effect," "Ordinary Course of Business," and other key terms, but does not assign a specific time period to the word "promptly."
The absence of a contractual definition requires resort to the standard interpretation of "promptly" under Delaware law and prevailing M&A practice. Under Delaware jurisprudence, "promptly" is generally understood to require action within a reasonable time after the obligor becomes aware of the triggering event, taking into account the totality of the circumstances. Courts have consistently interpreted "promptly" as requiring more expeditious action than "as soon as practicable" or "as soon as reasonably practicable" (which permit somewhat more time for logistical preparation and internal deliberation), but less immediate action than "immediately" (which implies same-day or within-hours performance). See, e.g., Hexion Specialty Chems., Inc. v. Huntsman Corp., 965 A.2d 715, 755–56 (Del. Ch. 2008) (analyzing interim covenant compliance obligations and the buyer's duty to act with reasonable diligence); Frontier Oil Corp. v. Holly Corp., 2005 WL 1039027, at *30 (Del. Ch. Apr. 29, 2005) (discussing the parties' obligations during the interim period between signing and closing).
In the context of M&A transactions involving clinical-stage pharmaceutical or biotechnology targets, the prevailing market standard for interim notification of material clinical developments is generally understood to require notification within one to two business days of the obligor's receipt of the triggering information, with more immediate notification (same day or next business day) expected in circumstances involving serious safety signals, regulatory actions, or other developments that may materially affect the value of the target's clinical assets. The specific inclusion of DMC recommendations in Section 5.1(b)(vi) suggests that the parties to this SPA contemplated — and intended — a heightened level of diligence and speed with respect to clinical trial developments, consistent with the centrality of VRD-4187 to the transaction rationale.
C. Related Provisions
Several additional provisions of the SPA are relevant to our analysis and are summarized below:
Section 5.1(a) — Ordinary Course Covenants. Section 5.1(a) requires Veridian to operate in the ordinary course of business consistent with past practice during the interim period between signing and closing, and to use commercially reasonable efforts to preserve intact the Company's business organization, relationships, and assets. While the notification obligations of Section 5.1(b) are analytically distinct from the operating covenants of Section 5.1(a), Veridian's response to the DMC findings — including its implementation of the enrollment suspension and dose modification — must also be evaluated under Section 5.1(a) for consistency with ordinary course requirements.
Section 7.2(a) — Representations and Warranties Closing Condition. Section 7.2(a) conditions Penterra's obligation to close on the accuracy of the Sellers' representations and warranties as of the Closing Date (with the accuracy of the representations and warranties qualified by a Material Adverse Effect standard, except for certain fundamental representations that must be true and correct in all respects). If the Marlowe Asset Management-2 interim analysis results render any of the Sellers' representations untrue or inaccurate — for example, the representations regarding the Company's clinical trials, regulatory compliance, or the absence of material undisclosed liabilities — the closing condition in Section 7.2(a) may not be satisfied.
Section 7.2(b) — No Material Adverse Effect Closing Condition. Section 7.2(b) conditions Penterra's obligation to close on the absence of any Material Adverse Effect since the date of the SPA. If the Marlowe Asset Management-2 interim analysis results constitute a Material Adverse Effect under the SPA's definition, this closing condition would not be satisfied.
Section 1.1 — Definition of "Material Adverse Effect." The SPA defines "Material Adverse Effect" as:
"any event, change, development, occurrence, condition, or effect that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (a) the business, results of operations, financial condition, or assets of the Company, taken as a whole, or (b) the ability of the Sellers to consummate the Transactions contemplated by this Agreement."
The definition contains customary carveouts for (i) general economic conditions, (ii) conditions generally affecting the biotechnology or pharmaceutical industry, (iii) changes in applicable law or regulations, (iv) changes in GAAP or other applicable accounting standards, (v) pandemics, epidemics, or public health emergencies, (vi) natural disasters, acts of war, terrorism, or similar events, and (vii) conditions arising from the announcement or pendency of the Transactions. Critically, the carveouts in clauses (i) through (vi) are subject to a "disproportionate impact" exception — i.e., an event falling within one of those carveouts may still constitute a Material Adverse Effect if it disproportionately affects the Company relative to other companies operating in the same industry or geographic markets. The Material Adverse Effect analysis is being addressed comprehensively in a separate memorandum expected on August 25, 2024.
Section 8.1(d) — Buyer's Termination Right. Section 8.1(d) provides that Penterra may terminate the SPA if any of Penterra's closing conditions set forth in Section 7.2 have not been satisfied or are incapable of being satisfied on or prior to the Outside Date of December 10, 2024, provided that such failure is not the result of a breach by Penterra of any of its obligations under the SPA. This termination right may be triggered by a failure of the representations and warranties closing condition (Section 7.2(a)), the no-Material-Adverse-Effect closing condition (Section 7.2(b)), or the covenant compliance closing condition (which requires that Veridian and the Sellers shall have performed and complied in all material respects with their covenants and obligations under the SPA).
IV. Analysis of Timeliness of Notification
A. When Did Veridian Learn of the DMC Findings?
The threshold question in evaluating the timeliness of Veridian's notification is when Veridian's management first became aware of the DMC's interim analysis findings and recommendation. The "promptly" standard runs from the date of the obligor's actual knowledge of the triggering event, not from the date of the event itself, though in practice the two will often coincide where the obligor's personnel are directly involved in the event.
Here, the evidence strongly supports the conclusion that Veridian's senior management had actual knowledge of the DMC findings no later than August 14, 2024 — the date on which the DMC conducted its interim analysis. The basis for this conclusion is as follows:
First, standard DMC procedures — including those reflected in the Marlowe Asset Management-2 DMC charter, which was made available to Penterra during due diligence — provide for real-time or near-real-time communication of DMC recommendations to the trial sponsor. The DMC's charter designates the sponsor's VP, Regulatory Affairs as the primary recipient of the DMC's recommendations, with a communication protocol requiring transmission of the DMC's conclusions within hours of the meeting's adjournment. In this case, Dr. Anne-Marie Fontaine, Veridian's VP, Regulatory Affairs, would have received the DMC's recommendation — including the recommendation to suspend enrollment and implement dose modifications — on August 14, 2024 itself or, at the latest, early on the morning of August 15, 2024.
Second, Dr. Fontaine's role as the designated recipient of DMC communications, combined with the severity and operational significance of the DMC's recommendations (which required immediate action to suspend enrollment), makes it virtually certain that she escalated the information to Dr. Julian Marek (CEO) and Dr. Priya Chandrasekaran (CSO) on the same day. A recommendation to suspend enrollment in a pivotal Phase II trial is not the type of information that would be held at the VP level for any meaningful period of time before escalation to the C-suite, particularly in a small, clinical-stage company like Veridian where the lead candidate is the subject of an active $900 million acquisition.
Third, we understand based on Veridian's prior disclosures during due diligence — including the clinical development governance presentation delivered to Penterra on May 15, 2024 — that Veridian's management team, including Drs. Marek, Chandrasekaran, and Fontaine, were present for or received real-time summaries of all DMC meetings relating to VRD-4187. If any of these individuals were present at or otherwise participated in the August 14 DMC meeting (as sponsors' representatives typically do, subject to the unblinding protocols), they would have had first-hand knowledge of the findings as of August 14.
Accordingly, we conclude that Veridian's management had actual knowledge of the DMC findings — including the elevated CRS incidence, the treatment-related deaths, the non-significant ORR data, and the DMC's recommendation to suspend enrollment — no later than August 14, 2024.
B. When Was Notification Delivered?
Penterra received Veridian's notification on August 16, 2024, by email from Rachel Stein-Goldberg (General Counsel, Veridian) to Thomas F. Holbrook (General Counsel, Penterra), with a copy to Natalie Reiner (SVP, Corporate Development, Penterra). A separate and contemporaneous communication was transmitted from Rebecca Whitmore (Zalcourt Archer & Cole LLP) to Oliver Mackenzie (Calderwood & Harkness LLP). The notification was thus delivered approximately two calendar days after the DMC interim analysis.
We note that August 14, 2024 was a Wednesday and August 16, 2024 was a Friday, meaning that the two-calendar-day gap corresponds to two business days. Email delivery is an acceptable method of providing written notice under the SPA's notice provisions (Section 10.2), and we do not raise any objection to the method of delivery.
C. Was the Two-Day Gap "Prompt"?
The central question is whether a two-calendar-day (two-business-day) gap between the DMC interim analysis on August 14 and the delivery of notification on August 16 satisfies the "promptly" standard under Section 5.1(b). This is a fact-intensive inquiry that depends on the totality of the circumstances, including the nature and severity of the triggering event, the complexity of the information to be communicated, and the parties' reasonable expectations.
Arguments Supporting Timeliness. Several considerations weigh in favor of the conclusion that Veridian's notification was timely:
First, two calendar days (or two business days) is generally within the range considered "prompt" in M&A practice. Courts applying Delaware law have not established a bright-line rule for the number of days within which "prompt" notification must occur, and the prevailing understanding in the transactional bar is that one to two business days constitutes a reasonable period for purposes of interim covenant notification obligations, absent unusual circumstances. See generally ABA Model Stock Purchase Agreement with Commentary (3d ed. 2021) at 245–47 (discussing notification timing standards in the interim period).
Second, Veridian may argue that it needed time to verify the accuracy of the DMC data, to prepare a meaningful summary of the findings for communication to Penterra, and to consult with its outside legal counsel at Zalcourt Archer & Cole LLP regarding the scope and format of the notification. The DMC's interim analysis would have generated a substantial volume of data, and Veridian may contend that delivering a hasty or incomplete summary on August 14 would have been less useful to Penterra than a considered communication delivered two days later.
Third, there is no direct evidence currently available to Penterra that Veridian deliberately delayed or concealed the DMC findings. While we have concerns about the completeness of the notification (discussed in Section V below), we do not have evidence at this time that the two-day delay was the product of bad faith or an intentional effort to withhold information from Penterra.
Arguments Supporting a Finding of Untimeliness. Notwithstanding the foregoing, several compelling considerations weigh against the conclusion that the two-day gap was sufficiently prompt:
First, and most significantly, the DMC findings were of exceptional severity and direct relevance to the transaction. The 23.4% incidence of Grade ≥3 CRS in the treatment arm — compared to 4.1% in the control arm — represents a dramatic and clinically meaningful safety signal. The seven treatment-related deaths in the VRD-4187 arm (3.6% of 194 patients) versus one death in the control arm (0.5% of 193 patients) represents a safety profile that could — and, as subsequently occurred, did — trigger FDA regulatory action. The non-statistically significant ORR (31.4% vs. 28.9%, p = 0.58) indicates that the efficacy benefit, if any, may not justify the elevated safety risk. Taken together, these findings represent a potentially company-altering event for a clinical-stage biotechnology company whose lead candidate constitutes the principal basis for the $900 million purchase price. In such circumstances, the "promptly" standard should be interpreted to require the most expeditious notification reasonably feasible.
Second, Section 5.1(b)(vi) specifically enumerates "any data monitoring committee recommendation" as a type of material clinical development triggering the notification obligation. The inclusion of this specific reference demonstrates that the parties to the SPA contemplated — and specifically bargained for — prompt notification of precisely this type of event. The negotiated specificity of Section 5.1(b)(vi) suggests a heightened expectation of speed relative to a general notification obligation, and Veridian cannot credibly claim surprise that DMC findings were subject to an expedited disclosure standard.
Third, the pendency of the acquisition created an acute need for Penterra to receive and process the DMC data as quickly as possible. Penterra's due diligence team — including Broadleaf Scientific Consulting LLC (Dr. Raymond Kapoor, Managing Director) — required time to evaluate the clinical significance of the findings, assess the regulatory implications, and advise Penterra's board of directors regarding the exercise of Penterra's contractual rights. Each day of delay in Veridian's notification reduced the time available for Penterra to conduct this evaluation and to make informed decisions regarding the transaction. The two-day delay was particularly consequential given that the DMC findings were received on a Wednesday, and Veridian's notification was not delivered until Friday afternoon, effectively deferring Penterra's substantive analysis to the following week.
Fourth, the nature of the DMC findings did not require extensive verification or analysis before notification could be provided. The DMC's recommendation to suspend enrollment and implement dose modifications was a discrete and unambiguous action that could have been communicated to Penterra within hours of its receipt by Veridian's management. Even if Veridian required additional time to prepare a comprehensive written summary of the underlying data, it could — and should — have provided at least a preliminary notification on August 14, alerting Penterra to the fact that the DMC had met, that it had identified a significant safety signal, and that a more detailed communication would follow. The SPA does not require that the initial notification be exhaustive; it requires that it be "prompt."
Our Assessment. On balance, while the two-day gap is not a clear-cut breach of the "promptly" standard, and reasonable minds may differ on whether this delay alone would constitute a material breach of Section 5.1(b), we believe that the gravity of the DMC findings, the specific inclusion of DMC recommendations in Section 5.1(b)(vi), and the practical need for Penterra to have timely access to the information all weigh in favor of the conclusion that Veridian should have provided, at a minimum, same-day or next-day preliminary notice. The failure to do so is a factor that, considered in the aggregate with the completeness deficiencies discussed below, supports Penterra's position that Veridian's performance under Section 5.1(b) was deficient and that such deficiency may constitute a breach of Veridian's covenants under the SPA.
V. Analysis of Completeness of Notification
A. Content of Veridian's August 16, 2024 Notification
As noted above, Veridian's notification was delivered by email from Rachel Stein-Goldberg (General Counsel, Veridian) to Thomas F. Holbrook (General Counsel, Penterra) on August 16, 2024, with a copy to Natalie Reiner. A full copy of the email is attached hereto as Appendix C. A separate, parallel communication from Rebecca Whitmore (Zalcourt Archer & Cole LLP) to Oliver Mackenzie (Calderwood & Harkness LLP) was delivered on the same date and is attached as Appendix D. The substantive content of both communications was largely consistent, and our analysis therefore focuses on the Stein-Goldberg email as the primary notification document.
Information Included in the Notification. The August 16 notification included the following information:
•  A general statement that the Marlowe Asset Management-2 DMC had conducted a pre-specified interim review of the trial data on August 14, 2024.
•  A statement that the DMC had recommended "modifications to the trial protocol," including a recommendation that enrollment be suspended pending further review and that dose modifications be implemented for patients currently receiving VRD-4187.
•  A reference to an "increased incidence of cytokine release syndrome in the treatment arm" relative to the control arm, characterized in general terms without specific quantification.
•  A statement that the findings were "preliminary" and that the Company was "implementing responsive measures in accordance with the DMC's recommendations and in consultation with the trial's principal investigators."
•  A statement that Veridian would "continue to provide updates as additional information becomes available."
Information Omitted or Understated. The notification was deficient in several critical respects:
•  No specific quantification of CRS incidence rates. The notification referenced an "increased incidence" of CRS in the treatment arm but did not disclose the specific incidence rates (23.4% in the VRD-4187 arm vs. 4.1% in the control arm) or the 19.3 percentage point differential. Without this quantitative data, Penterra was unable to independently assess the magnitude of the safety signal or to compare the CRS profile to that of other T-cell engager therapies in clinical development.
•  No mention of treatment-related deaths. This is the most significant omission in the notification. The notification made no reference whatsoever to the seven treatment-related deaths in the VRD-4187 arm (3.6% of 194 patients) or the one death in the control arm (0.5% of 193 patients). The treatment-related death count is the single most critical piece of safety data from the interim analysis, and its omission from the notification is a material deficiency that prevented Penterra from understanding the full severity of the safety signal. The omission is particularly concerning because the death data is the type of information most likely to trigger FDA regulatory action and to bear on the commercial viability and regulatory approvability of VRD-4187.
•  No disclosure of ORR data. The notification did not disclose the overall response rate data (31.4% vs. 28.9%, p = 0.58), which showed a non-statistically significant difference in efficacy between the treatment and control arms. This data is critical to Penterra's assessment of the risk-benefit profile of VRD-4187 because it indicates that the elevated safety risk of VRD-4187 may not be offset by a meaningful efficacy benefit. Omitting the efficacy data while referencing the safety findings in only general terms had the effect of presenting an incomplete and potentially misleading picture of the interim analysis results.
•  No disclosure of the DMC's specific language regarding the severity of the safety signal. The notification paraphrased the DMC's recommendations in general terms but did not convey the specific language used by the DMC in characterizing the safety signal or the basis for its recommendation to suspend enrollment. The DMC's specific findings and reasoning — as reflected in the DMC meeting minutes and interim analysis report — are essential to a full understanding of the clinical significance of the data.
•  No provision of underlying DMC report, meeting minutes, or statistical tables. The notification did not attach or reference the DMC's interim analysis report, meeting minutes, or the underlying statistical tables and analyses. These documents would have provided Penterra's clinical advisors (including Broadleaf Scientific Consulting) with the detailed data necessary to conduct an independent assessment of the findings.
B. Analysis Under Section 5.1(b)
The completeness of Veridian's notification must be evaluated under the specific requirements of Section 5.1(b), which imposes notification obligations with respect to multiple categories of events and developments.
Section 5.1(b)(vi): Material Clinical Trial Developments. Section 5.1(b)(vi) requires notification of "any material development relating to any pending clinical trial of the Company, including any data monitoring committee recommendation, adverse event report, or regulatory communication." The use of the word "including" indicates that DMC recommendations are a non-exhaustive example of the types of material clinical developments that must be disclosed, but the breadth of the clause — "any material development" — makes clear that the obligation extends to the full scope of the DMC's findings, not merely the headline recommendation. The DMC's recommendation to suspend enrollment and implement dose modifications is, standing alone, a material development. But the underlying data that prompted the recommendation — the CRS incidence rates, the treatment-related death count, and the ORR data — are equally material and must be disclosed to satisfy the notification obligation.
Veridian's notification disclosed the fact of the DMC's recommendation but omitted the substance of the underlying data. This is analogous to disclosing that a patient has been diagnosed with a serious illness while omitting the test results that form the basis of the diagnosis. The notification, while not entirely silent, was sufficiently incomplete to prevent Penterra from making an informed assessment of the materiality and significance of the DMC's findings. This constitutes a deficiency under Section 5.1(b)(vi).
Section 5.1(b)(i): Events Having or Reasonably Expected to Have a Material Adverse Effect. Section 5.1(b)(i) requires notification of "any event, circumstance, development, or occurrence arising after the date of this Agreement that has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect." The Marlowe Asset Management-2 interim analysis results — including the elevated CRS incidence, the treatment-related deaths, and the non-significant efficacy data — may constitute, individually or in the aggregate, a Material Adverse Effect under SPA § 1.1. For purposes of this notification analysis, the question is not whether a Material Adverse Effect has in fact occurred (that question is being addressed separately), but whether the information provided in the notification was sufficient to enable Penterra to make that assessment. By omitting the specific quantitative data — and, critically, the treatment-related death count — Veridian's notification deprived Penterra of the ability to evaluate whether a Material Adverse Effect had occurred. This is a deficiency that goes to the core purpose of Section 5.1(b)(i).
Section 5.1(b)(ii): Events Causing Representations to Be Untrue. Section 5.1(b)(ii) requires notification of any event that "would reasonably be expected to cause any representation or warranty of the Sellers set forth in Article III to be untrue or inaccurate in any material respect as of the Closing Date." The Sellers' representations in Article III include representations regarding the status and safety profile of the Company's clinical trials, the absence of material undisclosed adverse events, and the accuracy of the clinical data provided to Penterra in connection with the transaction. The Marlowe Asset Management-2 interim analysis results may render one or more of these representations untrue or inaccurate as of the Closing Date. Again, the notification should have been sufficiently detailed to enable Penterra to assess the implications for the Sellers' representations. The omissions identified above are deficiencies under this subsection as well.
The cumulative effect of these omissions is that Veridian's August 16, 2024 notification, while facially responsive to the notification obligation, was substantively inadequate. The notification conveyed the general fact that the DMC had met and recommended protocol modifications, but it omitted the most critical data points — the death count, the specific CRS rates, and the efficacy data — that Penterra needed to understand the full dimensions of the clinical setback and to evaluate its rights under the SPA.
C. Subsequent Information Requests
Following receipt of Veridian's August 16, 2024 notification, Penterra (acting through Calderwood & Harkness LLP) promptly requested additional detail from Veridian and Zalcourt Archer & Cole LLP. Specifically, on the afternoon of August 16 and on August 17, Oliver Mackenzie transmitted requests to Rebecca Whitmore for the following materials: (a) the full DMC interim analysis report; (b) DMC meeting minutes from August 14, 2024; (c) all adverse event reports filed for VRD-4187 since the date of the SPA; (d) statistical tables and analyses underlying the DMC's findings; and (e) any communications between Veridian and the FDA regarding the Marlowe Asset Management-2 trial since the date of the SPA.
As of the date of this memorandum, Veridian has provided limited supplemental information in response to these requests, and negotiations regarding the scope and timing of further disclosures are ongoing. The need for these follow-up requests — and the fact that Penterra was required to independently seek information that should have been included in the original notification — itself evidences the inadequacy of the initial notification. A notification that requires the recipient to immediately request supplemental detail in order to understand the significance of the notified event has not fulfilled the purpose of the notification obligation.
We further note that Broadleaf Scientific Consulting LLC (Dr. Raymond Kapoor, Managing Director) delivered its supplemental clinical assessment on August 19, 2024. While this assessment provided valuable context for Penterra's evaluation of the DMC findings, it was based in significant part on information obtained through Penterra's own follow-up efforts and independent analysis, rather than solely on the information provided in Veridian's notification. The fact that Penterra was compelled to mobilize its own clinical advisors to fill the informational gaps left by Veridian's notification underscores the deficiency of that notification.
VI. Implications for Penterra's Rights Under the SPA
A. Effect on Closing Conditions
As set forth in the savings clause of Section 5.1(b), the delivery of a notification does not cure any breach of any representation, warranty, covenant, or obligation under the SPA, does not limit or affect Penterra's rights or remedies, and does not satisfy any of the closing conditions in Section 7.2. This means that the inadequacy of Veridian's notification does not waive the underlying issue that gave rise to the notification obligation — i.e., the Marlowe Asset Management-2 DMC findings.
However, the deficiencies in Veridian's notification may be relevant to Penterra's closing condition arguments in two respects:
First, the notification deficiencies may constitute a breach of Veridian's covenants under Section 5.1(b). The covenant compliance closing condition in the SPA requires that Veridian and the Sellers shall have performed and complied in all material respects with their covenants and obligations under the SPA as a condition to Penterra's obligation to close. If Veridian's notification was not timely or not complete, as we have concluded, that failure may itself constitute a material breach of Section 5.1(b), which would result in a non-satisfaction of the covenant compliance closing condition independent of any Material Adverse Effect determination. While a court would likely evaluate the materiality of the notification deficiency in the context of the overall transaction, we believe that the omission of the treatment-related death count — the most critical piece of safety data from the interim analysis — is sufficiently significant to constitute a material breach of the notification covenant.
Second, the deficiencies in the notification may demonstrate a pattern of understatement or minimization of the VRD-4187 clinical problems by Veridian and its management. If Penterra ultimately seeks to terminate the SPA or to resist enforcement of a specific performance claim by Veridian, the notification deficiencies — and, in particular, the omission of the death data and the characterization of the findings as "preliminary" — may be adduced as evidence that Veridian was not forthcoming with Penterra during the interim period and that Penterra could not rely on the Sellers' representations and covenants. This evidence would be relevant to the equitable considerations that a Delaware court would weigh in evaluating any termination or specific performance dispute.
B. Effect on MAE Determination
The notification deficiencies are analytically separate from the substantive question of whether the Marlowe Asset Management-2 interim analysis results constitute a "Material Adverse Effect" under SPA § 1.1. The Material Adverse Effect analysis turns on the nature, severity, duration, and financial and operational impact of the clinical findings, evaluated against the contractual definition and its carveouts. That analysis is being conducted in a comprehensive memorandum currently in preparation and expected to be delivered on or about August 25, 2024.
Nonetheless, the notification deficiencies may bear indirectly on the Material Adverse Effect determination in the following respects:
First, Veridian's characterization of the DMC findings as "preliminary" may undermine any subsequent argument by Veridian that the findings should be viewed as non-material or as subject to change. If Veridian's own internal assessment of the findings was sufficiently serious to warrant consultation with outside counsel and a two-day deliberation period before notification (as appears to have occurred), it is difficult for Veridian to credibly maintain that the findings are merely "preliminary" and should be discounted.
Second, the omission of the treatment-related death count — the single most alarming data point from the interim analysis — may be cited by Penterra as evidence that Veridian itself understood the data to be devastating and was attempting to manage Penterra's reaction by controlling the flow of information. While we do not have direct evidence of this intent at present, the inference is available and may be deployed in any future dispute.
C. Effect on Termination Rights
If Veridian's notification deficiencies constitute a breach of SPA § 5.1(b), such breach may independently support a termination right under SPA § 8.1(d). Section 8.1(d) permits Penterra to terminate the SPA if any of Penterra's closing conditions are not satisfied or are incapable of being satisfied prior to the Outside Date of December 10, 2024, provided that the failure is not the result of Penterra's breach. A breach of the Section 5.1(b) notification covenant would result in a non-satisfaction of the covenant compliance closing condition, potentially triggering this termination right.
Importantly, a notification deficiency of this nature is not susceptible to retroactive cure. The obligation under Section 5.1(b) is to provide prompt and complete notification at the time the triggering event occurs. If Veridian failed to provide timely and complete notification of the August 14, 2024 DMC findings, that failure is a completed breach that cannot be undone by subsequent disclosures or by the provision of additional information in response to Penterra's follow-up requests. While Veridian may argue that the initial notification was adequate and that the subsequent provision of additional detail constitutes supplemental compliance, Penterra has a strong argument that the notification obligation requires sufficiency at the time of delivery, not in retrospect after the buyer has been forced to extract the information through its own efforts.
We note that the termination right under Section 8.1(d) is subject to the requirement that the failure of the closing condition be "incapable of being satisfied" prior to the Outside Date. Veridian may argue that any notification deficiency can be cured prospectively by providing the outstanding information. However, as noted above, the "promptly" requirement inherently cannot be cured retrospectively, and the failure to include the death data in the initial notification — regardless of whether it is subsequently provided — is a completed breach. Whether this breach, standing alone, would constitute a sufficient basis for termination under Section 8.1(d) is a question that would likely be evaluated by a court in light of the totality of the circumstances, including the significance of the omitted information and any prejudice suffered by Penterra as a result of the delay and incompleteness. We believe the argument is strongest when viewed in conjunction with the Material Adverse Effect and representation and warranty arguments being developed in the separate memorandum.
VII. Comparison to Industry Practice and Contractual Standards
It is useful to contextualize Veridian's notification against the prevailing standards of practice in comparable biopharmaceutical M&A transactions involving clinical-stage targets with active clinical trials during the interim period between signing and closing.
In transactions of this type, the interim period is recognized as a period of heightened informational asymmetry and vulnerability for the buyer, particularly where the target's valuation is predicated on clinical assets that remain subject to the inherent uncertainties of clinical development. Industry practice and the expectations of sophisticated transactional parties reflect this reality. The standard notification practice for clinical-stage targets with active trials — as reflected in published commentary, practitioner guides, and the informal consensus of the biopharmaceutical M&A bar — calls for immediate or same-day notification of DMC safety signals, particularly where the DMC has recommended enrollment suspension, dose modification, or early termination. This initial notification is typically followed by a more detailed written summary, including specific quantitative data, within 24 to 48 hours. The rationale for this two-step approach is that the buyer needs to know, as quickly as possible, that a material clinical event has occurred, even if the full details require additional time to compile and communicate. A preliminary notice alerts the buyer to the event, preserves the buyer's ability to mobilize its advisors, and demonstrates the seller's good faith compliance with the notification covenant.
Veridian's August 16, 2024 notification departed from this standard in two respects. First, no preliminary notification was provided on August 14 or August 15 — the first communication of any kind from Veridian to Penterra regarding the DMC interim analysis did not occur until August 16, two calendar days after the DMC meeting. Second, even when the notification was delivered on August 16, it was incomplete in the respects described above — omitting the death count, specific CRS rates, and ORR data. Thus, Veridian provided neither immediate preliminary notice nor a timely comprehensive summary. This falls at the lower end of acceptable practice and, given the severity of the safety findings (seven treatment-related deaths, a CRS incidence rate of 23.4%, and a non-significant efficacy signal), is difficult to defend as consistent with the expectations of a well-advised clinical-stage biotechnology company in the midst of a $900 million acquisition.
We also note the assessment of Dr. Raymond Kapoor of Broadleaf Scientific Consulting LLC, who advised Penterra on August 19, 2024 that the CRS incidence data and treatment-related death rate from the Marlowe Asset Management-2 interim analysis were of such clinical significance that any delay in disclosure would materially impair the ability of Penterra's clinical and regulatory advisors to conduct a meaningful and timely scientific evaluation. Dr. Kapoor specifically noted that the treatment-related death rate of 3.6% in the VRD-4187 arm was well above the threshold that would typically trigger immediate FDA scrutiny and that early access to the specific data — rather than a generalized summary — was essential to evaluating the likelihood of regulatory action. This assessment corroborates our conclusion that Veridian's notification was deficient in both timeliness and completeness.
VIII. Recommendations
Based on the foregoing analysis, we recommend the following actions:
A. Immediate Actions
1.  Formal Document Request. Calderwood & Harkness should send a formal written communication to Zalcourt Archer & Cole LLP, attention Rebecca Whitmore, requesting full and complete copies of the following materials:
(a) The Marlowe Asset Management-2 DMC interim analysis report generated in connection with the August 14, 2024 DMC meeting, including all appendices and exhibits thereto;
(b) The DMC meeting minutes from August 14, 2024, including any summary of discussions, deliberations, and the specific basis for the DMC's recommendations;
(c) All adverse event reports filed with respect to VRD-4187 since the date of the SPA (June 10, 2024), including all serious adverse event ("SAE") reports and all Individual Case Safety Reports ("ICSRs") submitted to the FDA or any other regulatory authority;
(d) All correspondence, communications, and filings between Veridian and the FDA regarding the Marlowe Asset Management-2 trial since the date of the SPA, including any safety reports, protocol amendment submissions, and informal communications with the FDA review division;
(e) Any protocol amendment drafts or submissions prepared or under preparation in response to the DMC's recommendations, including any proposed dose modification schedules or revised enrollment criteria.
This request should be framed as a demand pursuant to Penterra's information rights under Section 5.1(b) and the SPA's general cooperation provisions, and should include a statement that the initial August 16, 2024 notification was insufficient to satisfy Veridian's obligations under the SPA.
2.  Documentation and Preservation. Penterra should carefully document and preserve the complete timeline and content of all notifications received from Veridian, including the August 16, 2024 email from Rachel Stein-Goldberg, the August 16, 2024 communication from Rebecca Whitmore, and all subsequent communications. This record should include date- and time-stamped copies of all emails and attachments, a narrative summary of each communication, and a comparison of the information provided against the information required by Section 5.1(b). This documentation should be maintained in a format suitable for use in potential termination proceedings or litigation before the Delaware Court of Chancery.
3.  Coordination with Broadleaf Scientific Consulting. Penterra should continue to coordinate with Broadleaf Scientific Consulting LLC (Dr. Raymond Kapoor, Managing Director) to independently assess the DMC data as it becomes available, including any supplemental data produced by Veridian in response to the formal request described above. Broadleaf's assessment will be critical to Penterra's evaluation of the Material Adverse Effect question and to the preparation of any expert testimony that may be required in future proceedings.
B. Ongoing Monitoring
1.  Real-Time Compliance Tracking. Penterra should continue to track Veridian's compliance with all Section 5.1(b) notification obligations on a real-ti